Clinical Development at Gilead Sciences and Volunteer ID faculty at SF VAMC. Previously Transplant ID at CU Anschutz via Brigham and Women’s, MGH, Dana Farber, Duke Med, and Harvard. Views strictly my own 🇬🇷🏳️‍🌈https://bsky.app/profile/doctor-yiannis.bsky.socialhttps://bsky.app/profile/doctor-yiannis.bsky.social/post/3lfzylif7mk2chttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02081-6/abstract18 Jan 2025 19:00 +0000at://did:plc:fb44fl2fshr5mdhg336aatbt/app.bsky.feed.post/3lfzylif7mk2chttps://bsky.app/profile/doctor-yiannis.bsky.social/post/3lfqx2x25x22hhttps://jamanetwork.com/journals/jama/fullarticle/280675015 Jan 2025 04:39 +0000at://did:plc:fb44fl2fshr5mdhg336aatbt/app.bsky.feed.post/3lfqx2x25x22hhttps://bsky.app/profile/doctor-yiannis.bsky.social/post/3lerm6zygcc2eVery timely https://jamanetwork.com/journals/jama/fullarticle/282867702 Jan 2025 17:31 +0000at://did:plc:fb44fl2fshr5mdhg336aatbt/app.bsky.feed.post/3lerm6zygcc2ehttps://bsky.app/profile/doctor-yiannis.bsky.social/post/3ldp6z3mmzc2b#IDSky #TxID what is your center’s approach to EBV in mismatched SOT or HCT? If PET, at what VL threshold do you reduce IS and at what threshold do you start ritux? Are you seeing relapsed viremia or PTLD after ritux? Any difference in outcomes you are seeing between pts on VGCV ppx for CMV vs not?20 Dec 2024 01:05 +0000at://did:plc:fb44fl2fshr5mdhg336aatbt/app.bsky.feed.post/3ldp6z3mmzc2b